California Veterinary Medical Board faces public outcry over Labrela safety concerns

Public concern over the controversial veterinary drug Labrela took center stage during the Veterinary Medical Board meeting on January 15, 2025. Deb Zummerlin, a concerned pet owner, voiced her distress over the drug's adverse effects, claiming it led to the death of her dog after multiple injections. Zummerlin urged the board to consider banning Labrela in California, citing alarming statistics that showed a rise in adverse reactions from 22,000 to over 24,000 in just a few months. She emphasized the need for veterinarians to be fully informed about the drug's risks and for pet owners to consent to its use after reviewing a comprehensive list of potential side effects.

Following Zummerlin's emotional testimony, the board moved on to other agenda items, including updates from the Department of Consumer Affairs (DCA) and a budget report. Melissa Gere, deputy director of board and bureau relations, provided insights into the governor's proposed budget for 2025-26, which includes plans for a new consumer protection agency aimed at enhancing regulatory efficiency.

The meeting also addressed changes in filing requirements for board members, who must now submit their Form 700 electronically, a shift aimed at streamlining processes. Harmony DiFilippo from the DCA budget office presented the board's expenditure projections, highlighting a projected fund balance of over $9.8 million for the upcoming fiscal year.

As the meeting concluded, the board acknowledged the importance of addressing public concerns regarding veterinary practices and the implications of new regulations. The discussions underscored a commitment to consumer protection and the ongoing evaluation of veterinary drugs, setting the stage for future deliberations on Labrela and its impact on animal health in California.